Nektar Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) has commenced a proposed underwritten public offering of $250,000,000 of common stock and, in lieu of common shares for certain investors, pre-funded warrants. Nektar may grant underwriters a 30-day option to purchase up to an additional $37,500,000 of common stock.
Proceeds are intended for general corporate purposes, including R&D and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The offering is subject to market conditions and may not be completed as proposed.
Positive
- $250M capital raise initiated
- Optional $37.5M underwriter greenshoe capacity
- Proceeds targeted to Phase 3 trials for rezpegaldesleukin
Negative
- Offering may cause shareholder dilution
- Completion is subject to market and other conditions
News Market Reaction – NKTR
On the day this news was published, NKTR declined 2.18%, reflecting a moderate negative market reaction. Argus tracked a peak move of +22.7% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $70M from the company's valuation, bringing the market cap to $3.13B at that time. Trading volume was very high at 4.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NKTR faced an offering announcement while peer moves were mixed: scanner data only flagged ABUS moving down, with no broad biotechnology momentum signal and no same-day peer news.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Offering closed | Neutral | +3.5% | Closed $460M equity offering including full exercise of underwriters’ option. |
| Feb 11 | Offering priced | Neutral | +7.0% | Priced upsized $400M public offering with 30-day underwriter option. |
| Feb 10 | Offering proposed | Neutral | +18.5% | Proposed $300M offering plus $45M underwriter option for development funding. |
| Jul 02 | Offering closed | Neutral | -3.0% | Closed $115M stock offering including full exercise of underwriters’ option. |
| Jul 01 | Offering priced | Neutral | -4.8% | Priced $100M offering at $23.50 per share with 30-day upsize option. |
Offering-related announcements have previously coincided with notable price moves, with an average move of 4.22% across recent capital-raising events.
Over the last year, Nektar has repeatedly tapped equity markets, with five offering-tagged releases ranging from a $100M deal in July 2025 to a $460M public offering in February 2026. These financings used common stock and pre-funded warrants, often with 30-day underwriter options and led by Jefferies, TD Cowen, and Piper Sandler. Price reactions to these offerings varied but averaged a 4.22% move, framing today’s proposed raise as part of a continuing capital-access strategy.
Historical Comparison
In recent cycles, NKTR issued 5 offering-related releases with an average move of 4.22%, placing this new proposed raise within a well-established financing pattern.
The company has progressed through multiple equity financings, from mid-2025 raises to larger February 2026 offerings, consistently using common stock and pre-funded warrants to support late-stage rezpegaldesleukin development.
Market Pulse Summary
This announcement outlines a proposed $250,000,000 underwritten offering, with an additional $37,500,000 underwriter option, to fund general corporate purposes and Phase 3 rezpegaldesleukin programs. Historically, Nektar has relied on multiple offerings to support late-stage trials and its immunotherapy pipeline. Investors may monitor final deal terms, completion of the transaction, and subsequent updates on Phase 3 timelines and development milestones when assessing ongoing capital needs.
Key Terms
underwritten public offering financial
pre-funded warrants financial
prospectus supplement regulatory
Phase 3 trials medical
AI-generated analysis. Not financial advice.
Nektar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development, clinical development (including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata) and manufacturing costs to support the advancement of its drug candidates, as well as other general corporate purposes.
Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering.
The securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-291466) that was filed with the
A preliminary prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which can be identified by words such as: "will," "expect," "develop," "potential," "plan," and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the size and expected gross proceeds from the offering, completion and timing of the public offering, the anticipated use of proceeds from the offering and the expectation to grant the underwriters a 30-day option to purchase additional shares. Nektar intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Nektar's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of Nektar. The actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the actual results to differ materially from those indicated in the forward-looking statements include, among others, the risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2026 as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statement made by Nektar in this press release is based only on information currently available to Nektar and speaks only as of the date on which it is made. Nektar undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-proposed-public-offering-302747681.html
SOURCE Nektar Therapeutics